| Name | Title | Contact Details |
|---|---|---|
Ashok Marín |
Chief Legal Officer | Profile |
Melissa Lozner |
Chief Compliance and Ethics Officer | Profile |
Ashok Marin |
Chief Legal Officer | Profile |
Improving the lives of people with severe illness or injury takes more than skill and compassion - it takes innovation. A national leader in long term acute care, LifeCare was built on the belief that early and aggressive intervention, coupled with a personalized treatment plan that encompasses body, mind and soul, can maximize a patient`s potential for recovery. Our multi-disciplinary treatment teams are directed by highly-trained, committed physicians and include healthcare professionals involved in all aspects of a patient`s care: nurses, respiratory therapists, physical medicine specialists, radiologists, pharmacists, dietitians and case managers. Our philosophy has impacted the lives of thousands of LifeCare patients, resulting in improved outcomes, shorter hospital stays and more cost-effective treatment. Based in Plano, Texas, the LifeCare Family of Hospitals includes both freestanding and "hospital-in-hospital" acute care hospitals designed to treat medically complex patients who require acute care hospital services for an extended period of time. Currently, our network includes 24 locations in 9 states.
Gensource-Rx is a Carlstadt, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BOCA PHARMACAL INC is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hudson Botanical Processing is a full-service cannabis manufacturing company serving the operational needs of the cannabis industry. They work with industry-leading cannabis brands to produce and distribute the highest quality products in Massachusetts.
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.